$PCYN
PROCYON CORP Stock $pcyn

$pcyn Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-K Financial Statement

#000143774923027045 Filed on September 28, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2023
Revenue	$1.173M	$1.202M	$4.687M
YoY Change	-0.22%	-0.59%	-3.22%
Cost Of Revenue	$260.7K	$265.2K	$1.117M
YoY Change	-11.6%	-20.18%	-17.66%
Gross Profit	$912.4K	$937.0K	$3.570M
YoY Change	3.59%	6.83%	2.4%
Gross Profit Margin	77.78%	77.94%	76.16%
Selling, General & Admin	$491.8K	$940.2K	$1.807M
YoY Change	15.96%	-4.43%	5.63%
% of Gross Profit	53.9%	100.34%	50.62%
Research & Development			$30.60K
YoY Change			2.0%
% of Gross Profit			0.86%
Depreciation & Amortization	$19.15K	$19.34K	$52.82K
YoY Change	75.52%	85.96%	38.2%
% of Gross Profit	2.1%	2.06%	1.48%
Operating Expenses	$491.8K	$940.2K	$1.838M
YoY Change	15.96%	-4.42%	5.57%
Operating Profit	-$57.39K	-$3.150K	-$97.38K
YoY Change	401.1%	-97.05%	-58.95%
Interest Expense	$5.208K	$4.870K	$11.82K
YoY Change	481.9%	1375.76%
% of Operating Profit
Other Income/Expense, Net	$14.17K	$8.820K	$32.01K
YoY Change	1482.79%		1674.22%
Pretax Income	-$43.23K	$10.53K	-$65.37K
YoY Change	309.41%	-109.91%	-72.23%
Income Tax	-$9.370K	$3.040K	-$15.13K
% Of Pretax Income		28.87%
Net Earnings	-$33.86K	$7.491K	-$50.25K
YoY Change	313.52%	-109.44%	-76.05%
Net Earnings / Revenue	-2.89%	0.62%	-1.07%
Basic Earnings Per Share	-$0.01		-$0.01
Diluted Earnings Per Share	-$0.01	$0.00	-$0.01
COMMON SHARES
Basic Shares Outstanding	8.087M	8.087M	8.087M
Diluted Shares Outstanding	8.108M		8.087M

Balance Sheet

Concept	2023 Q3	2023 Q2	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$969.1K	$1.014M	$1.014M
YoY Change	11.93%	-2.66%	-2.66%
Cash & Equivalents	$402.5K	$451.3K
Short-Term Investments	$566.6K	$562.5K	$562.5K
Other Short-Term Assets	$215.7K	$298.5K	$298.5K
YoY Change	-13.39%	-20.37%	-20.37%
Inventory	$544.3K	$431.4K	$431.4K
Prepaid Expenses
Receivables	$434.3K	$494.0K	$494.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$2.163M	$2.238M	$2.238M
YoY Change	-10.53%	-13.44%	-13.44%
LONG-TERM ASSETS
Property, Plant & Equipment	$315.3K	$281.0K	$808.2K
YoY Change	110.47%	82.84%	-6.01%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$462.3K	$500.9K	$500.9K
YoY Change	35.79%	47.07%	47.07%
Total Long-Term Assets	$1.275M	$1.326M	$1.326M
YoY Change	9.11%	8.93%	8.92%
TOTAL ASSETS
Total Short-Term Assets	$2.163M	$2.238M	$2.238M
Total Long-Term Assets	$1.275M	$1.326M	$1.326M
Total Assets	$3.438M	$3.564M	$3.564M
YoY Change	-4.13%	-6.28%	-6.28%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$172.2K	$175.1K	$175.1K
YoY Change	49.82%	-1.7%	-1.7%
Accrued Expenses	$396.2K	$451.1K	$451.1K
YoY Change	9.27%	-3.03%	-3.03%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$568.4K	$626.1K	$626.1K
YoY Change	19.02%	-2.66%	-2.66%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$275.4K	$319.9K	$319.9K
YoY Change	-38.68%	-34.89%	-34.89%
Total Long-Term Liabilities	$275.4K	$319.9K	$319.9K
YoY Change	-38.68%	-34.89%	-34.89%
TOTAL LIABILITIES
Total Short-Term Liabilities	$568.4K	$626.1K	$626.1K
Total Long-Term Liabilities	$275.4K	$319.9K	$319.9K
Total Liabilities	$843.8K	$946.0K	$946.0K
YoY Change	-8.94%	-16.62%	-16.62%
SHAREHOLDERS EQUITY
Retained Earnings	-$2.023M	-$1.989M
YoY Change	3.9%	2.59%
Common Stock	$4.450M	$4.445M
YoY Change	0.12%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$2.595M	$2.618M	$2.618M
YoY Change
Total Liabilities & Shareholders Equity	$3.438M	$3.564M	$3.564M
YoY Change	-4.13%	-6.28%	-6.28%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2023
OPERATING ACTIVITIES
Net Income	-$33.86K	$7.491K	-$50.25K
YoY Change	313.52%	-109.44%	-76.05%
Depreciation, Depletion And Amortization	$19.15K	$19.34K	$52.82K
YoY Change	75.52%	85.96%	38.2%
Cash From Operating Activities	$4.585K	$157.7K	$145.5K
YoY Change	-103.56%	1407.84%	-163.4%
INVESTING ACTIVITIES
Capital Expenditures	$53.41K	$154.1K	$180.1K
YoY Change	662.6%	-781.34%	117.97%
Acquisitions
YoY Change
Other Investing Activities		$2.860K	-$274.4K
YoY Change
Cash From Investing Activities	-$53.41K	-$151.2K	-$454.6K
YoY Change	662.6%	568.69%	450.02%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$0.00	121.0K	$0.00
YoY Change	-100.0%	-423.16%	-100.0%
NET CHANGE
Cash From Operating Activities	$4.585K	157.7K	$145.5K
Cash From Investing Activities	-$53.41K	-151.2K	-$454.6K
Cash From Financing Activities	$0.00	121.0K	$0.00
Net Change In Cash	-$48.82K	127.5K	-$309.1K
YoY Change	-72.25%	-357.15%	-33.69%
FREE CASH FLOW
Cash From Operating Activities	$4.585K	$157.7K	$145.5K
Capital Expenditures	$53.41K	$154.1K	$180.1K
Free Cash Flow	-$48.82K	$3.670K	-$34.67K
YoY Change	-64.08%	-88.9%	-88.89%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	us-gaap	Rental Income Nonoperating RentalIncomeNonoperating	20191	usd
CY2022	us-gaap	Rental Income Nonoperating RentalIncomeNonoperating	0	usd
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0000812306
CY2023Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	0	usd
CY2023	pcyn	Percentage Of Discount On Bill Payment Within Ten Days To Physicians PercentageOfDiscountOnBillPaymentWithinTenDaysToPhysicians	0.02	pure
CY2023	pcyn	Percentage Of Discount On Bill Payment Within Ten Days To Pharmaceutical Distributors And Drug Stores PercentageOfDiscountOnBillPaymentWithinTenDaysToPharmaceuticalDistributorsAndDrugStores	0.02	pure
CY2023	pcyn	Number Of Wholly Owned Subsidiaries NumberOfWhollyOwnedSubsidiaries	2	pure
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	180109	usd
CY2023	pcyn	Increase Decrease In Operating Lease Rightofuse Asset IncreaseDecreaseInOperatingLeaseRightofuseAsset	180109	usd
CY2022Q2	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2023Q2	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2023	dei	Auditor Firm AuditorFirmId	232
CY2023	dei	Auditor Name AuditorName	Ferlita, Walsh, Gonzalez & Rodriguez, P.A.
CY2023	dei	Auditor Location AuditorLocation	Tampa, Florida
CY2023Q2	us-gaap	Cash Cash	451306	usd
CY2022Q2	us-gaap	Cash Cash	760396	usd
CY2023Q2	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	562472	usd
CY2022Q2	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	281105	usd
CY2023Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	11625	usd
CY2022Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	13569	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	493953	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	407085	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	431405	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	761651	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	298469	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	374817	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	2237605	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	2585054	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	281023	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	153702	usd
CY2023Q2	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	9220	usd
CY2022Q2	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	12311	usd
CY2023Q2	us-gaap	Inventory Noncurrent InventoryNoncurrent	330513	usd
CY2022Q2	us-gaap	Inventory Noncurrent InventoryNoncurrent	182224	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	17000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	17000	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	527170	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	706155	usd
CY2023Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	0	usd
CY2022Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	31960	usd
CY2023Q2	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	161180	usd
CY2022Q2	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	146051	usd
CY2023Q2	pcyn	Assets Noncurrent Excluding Property Plant And Equipment AssetsNoncurrentExcludingPropertyPlantAndEquipment	1045083	usd
CY2022Q2	pcyn	Assets Noncurrent Excluding Property Plant And Equipment AssetsNoncurrentExcludingPropertyPlantAndEquipment	1063741	usd
CY2023Q2	us-gaap	Assets Assets	3563711	usd
CY2022Q2	us-gaap	Assets Assets	3802497	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	175057	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	178083	usd
CY2023Q2	pcyn	Accrued Liabilities And Employee Related Liabilities Current AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent	277498	usd
CY2022Q2	pcyn	Accrued Liabilities And Employee Related Liabilities Current AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent	302601	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	173565	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	162547	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	626120	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	643231	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	319882	usd
CY2023Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	319882	usd
CY2022Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	491312	usd
CY2023Q2	us-gaap	Liabilities Liabilities	946002	usd
CY2022Q2	us-gaap	Liabilities Liabilities	1134543	usd
CY2023Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	496000000
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	496000000
CY2023Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	80000000
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	80000000
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8087388
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8087388
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8087388
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8087388
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	4444766	usd
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	4444766	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	35564	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	35564	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1989481	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1939236	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	2617709	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	2667954	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3563711	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3802497	usd
CY2023	us-gaap	Revenues Revenues	4686659	usd
CY2022	us-gaap	Revenues Revenues	4842433	usd
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1117072	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1356612	usd
CY2023	us-gaap	Gross Profit GrossProfit	3569587	usd
CY2022	us-gaap	Gross Profit GrossProfit	3485821	usd
CY2023	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	1859980	usd
CY2022	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	2012430	usd
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1806988	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1710606	usd
CY2022	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	3723036	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	11816	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	1804	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	32007	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1804	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-65374	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-235411	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-15129	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-25621	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-50245	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-209790	usd
CY2023	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	16710	usd
CY2022	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	16710	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-66955	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-226500	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8087388
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8087388
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8087388
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8087388
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	2667954	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-8187	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	2659767	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-20078	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	2639689	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-29471	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	2610218	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	7491	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	2617709	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	2877744	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	42482	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-79362	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	2667954	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-50245	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-209790	usd
CY2023	us-gaap	Depreciation Depreciation	52817	usd
CY2022	us-gaap	Depreciation Depreciation	38217	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-1944	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	4161	usd
CY2023	pcyn	Operating Lease Right Of Use Asset Amortization Expense Reversal OperatingLeaseRightOfUseAssetAmortizationExpenseReversal	178985	usd
CY2022	pcyn	Operating Lease Right Of Use Asset Amortization Expense Reversal OperatingLeaseRightOfUseAssetAmortizationExpenseReversal	176189	usd
CY2023	pcyn	Accrued Interest On Certificates Of Deposit AccruedInterestOnCertificatesOfDeposit	6949	usd
CY2022	pcyn	Accrued Interest On Certificates Of Deposit AccruedInterestOnCertificatesOfDeposit	667	usd
CY2023	pcyn	Deferred Income Tax Expense Benefit Gross DeferredIncomeTaxExpenseBenefitGross	16831	usd
CY2022	pcyn	Deferred Income Tax Expense Benefit Gross DeferredIncomeTaxExpenseBenefitGross	-57581	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	31960	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-31960	usd
CY2023	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	-0	usd
CY2022	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	-0	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-0	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-0	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	0	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	0	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	84924	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-86112	usd
CY2023	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	-3091	usd
CY2022	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	9076	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-181957	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	89537	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-76348	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	98566	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3026	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	10495	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-25103	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-111376	usd
CY2023	pcyn	Operating Lease Principal Payments OperatingLeasePrincipalPayments	160412	usd
CY2022	pcyn	Operating Lease Principal Payments OperatingLeasePrincipalPayments	154023	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	145466	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-383482	usd
CY2023	pcyn	Payments For Purchases Of Cd PaymentsForPurchasesOfCD	400000	usd
CY2023	pcyn	Payments For Redemption Of Certificates Of Deposit PaymentsForRedemptionOfCertificatesOfDeposit	-125582	usd
CY2022	pcyn	Payments For Redemption Of Certificates Of Deposit PaymentsForRedemptionOfCertificatesOfDeposit	-0	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	180138	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	82644	usd
CY2023	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-454556	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-82644	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-309090	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-466126	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	451306	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	760396	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Use of Estimates</b></p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Concentration of Credit Risk</b></p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company maintains its cash at various financial institutions. All accounts are fully insured by the Federal Deposit Insurance Corporation, up to $250,000 per Company. At June 30, 2023 and 2022, our uninsured cash balance was $0 and $52,539 respectively.</p>
CY2023Q2	us-gaap	Cash Uninsured Amount CashUninsuredAmount	0	usd
CY2022Q2	us-gaap	Cash Uninsured Amount CashUninsuredAmount	52539	usd
CY2023	pcyn	Term Of Sale For Pharmaceutical Distributors And Drug Stores TermOfSaleForPharmaceuticalDistributorsAndDrugStores	P30D
CY2023	pcyn	Standard Payment Term To Physicians StandardPaymentTermToPhysicians	P30D
CY2023Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	11600	usd
CY2022Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	13600	usd
CY2022Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	31960	usd
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	115000
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.26
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	0
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	115000
CY2022Q2	us-gaap	Accrued Vacation Current AccruedVacationCurrent	41837	usd
CY2023Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	48793	usd
CY2022Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	53681	usd
CY2023Q2	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	24387	usd
CY2022Q2	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	10789	usd
CY2023Q2	pcyn	Accrued Lease Liability AccruedLeaseLiability	92856	usd
CY2022Q2	pcyn	Accrued Lease Liability AccruedLeaseLiability	40439	usd
CY2023Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	7344	usd
CY2022Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4514	usd
CY2023Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	277498	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.26
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	0
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	115000
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.26
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	115000
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.26
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	115000
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.26
CY2023Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	576548	usd
CY2022Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	759118	usd
CY2023Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	185370	usd
CY2022Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	184757	usd
CY2023Q2	us-gaap	Inventory Gross InventoryGross	761918	usd
CY2022Q2	us-gaap	Inventory Gross InventoryGross	943875	usd
CY2023Q2	us-gaap	Inventory Noncurrent InventoryNoncurrent	330513	usd
CY2022Q2	us-gaap	Inventory Noncurrent InventoryNoncurrent	182224	usd
CY2022Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	302601	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	606883	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	325860	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	281023	usd
CY2023	us-gaap	Depreciation Depreciation	52817	usd
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	426745	usd
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	273043	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	153702	usd
CY2022	us-gaap	Depreciation Depreciation	38217	usd
CY2023Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	70298	usd
CY2022Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	151341	usd
CY2023Q2	us-gaap	Accrued Vacation Current AccruedVacationCurrent	33820	usd
CY2021Q2	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	250000	usd
CY2023Q2	us-gaap	Line Of Credit LineOfCredit	0	usd
CY2023	us-gaap	Interest Expense Debt InterestExpenseDebt	0	usd
CY2022	us-gaap	Interest Expense Debt InterestExpenseDebt	0	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	184805	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	188353	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	141062	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10721	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	0	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-50245	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-209790	usd
CY2023	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	16710	usd
CY2022	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	16710	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-66955	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-226500	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-66955	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-226500	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8087388
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8087388
CY2023	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0
CY2022	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0
CY2023	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	0
CY2022	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	0
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8087388
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8087388
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
CY2023Q2	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	716000	usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	31960	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-31960	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-15129	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-25621	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	12535	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	21229	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	2594	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	4392	usd
CY2023	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	15129	usd
CY2022	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	25621	usd
CY2023Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	181439	usd
CY2023Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	6387	usd
CY2023Q2	pcyn	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	125064	usd
CY2023Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Compensated Absences DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences	8572	usd
CY2023Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Bonuses DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses	6181	usd
CY2023Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	2946	usd
CY2023Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	330589	usd
CY2023Q2	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	133611	usd
CY2023Q2	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	35798	usd
CY2023Q2	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	169409	usd
CY2023Q2	pcyn	Deferred Tax Assets Liabilities Gross DeferredTaxAssetsLiabilitiesGross	161180	usd
CY2023Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	0	usd
CY2023Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	161180	usd
CY2023Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	-0	usd
CY2022Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	31960	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	31960	usd
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.2535	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.2535	pure
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	13767	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	49436	usd
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	2848	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	10229	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	-1246	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	-689	usd
CY2023	us-gaap	Income Tax Reconciliation Tax Exempt Income IncomeTaxReconciliationTaxExemptIncome	-0	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Exempt Income IncomeTaxReconciliationTaxExemptIncome	-0	usd
CY2023	pcyn	Effective Income Tax Rate Reconciliation Loss Carryforward Amount EffectiveIncomeTaxRateReconciliationLossCarryforwardAmount	32200	usd
CY2022	pcyn	Effective Income Tax Rate Reconciliation Loss Carryforward Amount EffectiveIncomeTaxRateReconciliationLossCarryforwardAmount	1395	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	30600	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	30000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.0425	pure
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	979744	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	452574	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	527170	usd
CY2015Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	979744	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	486297	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	493447	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	173565	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	319882	usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	202270	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	208467	usd
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y8M23D
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0329	pure
CY2023	us-gaap	Sublease Income SubleaseIncome	19908	usd
CY2023Q2	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	14220	usd
CY2023Q2	us-gaap	Lessor Operating Lease Payments To Be Received Two Years LessorOperatingLeasePaymentsToBeReceivedTwoYears	0	usd
CY2023Q2	us-gaap	Lessor Operating Lease Payments To Be Received Three Years LessorOperatingLeasePaymentsToBeReceivedThreeYears	0	usd
CY2023Q2	us-gaap	Lessor Operating Lease Payments To Be Received Four Years LessorOperatingLeasePaymentsToBeReceivedFourYears	0	usd
CY2023Q2	us-gaap	Lessor Operating Lease Payments To Be Received Five Years LessorOperatingLeasePaymentsToBeReceivedFiveYears	0	usd
CY2023Q2	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	14220	usd

Files In Submission

Name	View Source	Status
pcyn-20230630_pre.xml	Edgar Link	unprocessable
pcyn-20230630_cal.xml	Edgar Link	unprocessable
0001437749-23-027045-index-headers.html	Edgar Link	pending
0001437749-23-027045-index.html	Edgar Link	pending
0001437749-23-027045.txt	Edgar Link	pending
0001437749-23-027045-xbrl.zip	Edgar Link	pending
ex_571925.htm	Edgar Link	pending
ex_571926.htm	Edgar Link	pending
ex_571927.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
pcyn-20230630.xsd	Edgar Link	pending
pcyn20230630_10k.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
pcyn-20230630_lab.xml	Edgar Link	unprocessable
pcyn-20230630_def.xml	Edgar Link	unprocessable
pcyn20230630_10k_htm.xml	Edgar Link	completed
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PCYN
PROCYON CORP Stock $pcyn

2023 Q3 Form 10-K Financial Statement

#000143774923027045 Filed on September 28, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PCYN PROCYON CORP Stock $pcyn

2023 Q3 Form 10-K Financial Statement

#000143774923027045 Filed on September 28, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PCYN
PROCYON CORP Stock $pcyn